Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05747014
Other study ID # MDT 22031
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 9, 2023
Est. completion date December 13, 2023

Study information

Verified date March 2024
Source Medtronic Surgical Technologies
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The Novapak study is a prospective, observational, multi-site, non-controlled, non-randomized, case-series, with a 2 week and 1-month follow-up in adults undergoing nasal/sinus surgery with Novapak Nasal Sinus Packing and Stent device used as indicated post-operatively and is being conducted to obtain clinical data on the safety and effectiveness of the Novapak device under use as intended in the device indications.


Description:

The primary objective is to assess the safety of the Novapak Nasal Sinus Packing and Stent device used as indicated post-operatively in patients undergoing nasal/sinus surgery by: - Collecting all AEs directly attributed to the device and/or those that cannot be determined; and calculating a point estimate and confidence interval - Collecting all AEs and calculating an overall rate and safety profile for the device The secondary objectives are to confirm device effectiveness through assessing adhesions, bleeding, healing and health during the procedure, 2 weeks and 1-month post treatment.


Recruitment information / eligibility

Status Completed
Enrollment 86
Est. completion date December 13, 2023
Est. primary completion date December 13, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Subject is at least 18 years of age. 2. Subject undergoing nasal/sinus surgery with the intended need for nasal sinus packing (i.e., Novapak). 3. After being informed of the nature of the study; the subject understands, agrees to its provisions, is willing to participate and provide written consent. 4. Mentally stable and able to follow the instructions for self-assessment/questionnaire completion. Exclusion Criteria: 1. Subject has a shellfish allergy. 2. Subject has known bleeding disorder or prescribed anticoagulants. 3. Subject has craniofacial abnormalities that may interfere with access to the sinuses. 4. Subject is immunocompromised (e.g., taking immunosuppressive medication). 5. Subject is participating in another investigational device, biologic, or drug study and has not completed the primary endpoint(s) or if there is a potential for clinical interference beyond the primary endpoint.

Study Design


Intervention

Device:
Novapak Nasal Sinus Packing and Stent
Potential subjects will have the need to undergo nasal/sinus surgery using a space-occupying stent and will perform daily self-saline nasal irrigations.

Locations

Country Name City State
Canada St. Joseph's Health Care London Onterio
United States ENT Associates of South Florida Boca Raton Florida
United States University of Miami Miami Florida
United States University of South Florida Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
Medtronic Surgical Technologies

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Novapak Safety Assessment Outcome Measure #1 for the Primary Outcome is the total number of Adverse Events that are directly attributed to the device and/or those that cannot be determined. 30 days
Primary Novapak Safety Assessment Outcome Measure #2 for the Primary Outcome is the total number of Adverse Events. 30 days
Secondary Novapak Effectiveness Assessment Outcome Measure #3 for the Secondary Outcome Measures is number of adhesions from procedure through 1-month post treatment. 30 days
Secondary Novapak Effectiveness Assessment Outcome Measure #4 for the Secondary Outcome Measures is the graded percentage of vertical height of the middle turbinate taken up by the adhesion using an ordinal scale (0-3) from procedure through 1-month post treatment. 30 days
Secondary Novapak Effectiveness Assessment Outcome Measure #5 for the Secondary Outcome Measures is to measure control of bleeding by comparing Boezaart Surgical Field Grading Scale scores post operatively, prior to Novapak insertion and post Novapak insertion. 1 day
Secondary Novapak Effectiveness Assessment Outcome Measure #6 for the Secondary Outcome Measures is to measure healing by comparing Lund-Kennedy scores before surgery and at 2 weeks and 1-month post treatment. 30 day
Secondary Novapak Effectiveness Assessment Outcome Measure #7 for the Secondary Outcome Measures is to measure health by comparing subject scores from the SNOT-22 questionnaire before surgery and at 2 weeks and 1-month post treatment. 30 day
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01960816 - InFlux System for Nasal Breathing Improvement N/A
Enrolling by invitation NCT03233373 - Thermal Imaging as a Potential Diagnostic Tool of Nasal Airflow
Recruiting NCT05527652 - Self-Supporting Nasopharyngeal Airway (ssNPA) Treating Upper Airway Obstruction in Hypotonia N/A
Recruiting NCT06163404 - Open-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant N/A
Active, not recruiting NCT04549545 - Vivaer® Procedure for Treatment of Nasal Airway Obstruction Study N/A
Active, not recruiting NCT05446714 - Evaluation of the Effect of Three Types of Rapid Maxillary Expanders (Conventional, Hybrid and MSE) N/A